Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E34.59 EPS (ttm)11.01 Insider Own0.40% Shs Outstand107.88M Perf Week1.96%
Market Cap41.08B Forward P/E22.68 EPS next Y16.79 Insider Trans-22.36% Shs Float79.46M Perf Month-8.28%
Income1.28B PEG2.11 EPS next Q4.49 Inst Own70.90% Short Float2.68% Perf Quarter-14.45%
Sales5.52B P/S7.45 EPS this Y39.50% Inst Trans-0.88% Short Ratio2.35 Perf Half Y-20.04%
Book/sh56.71 P/B6.71 EPS next Y7.83% ROA16.20% Target Price458.78 Perf Year3.15%
Cash/sh12.78 P/C29.79 EPS next 5Y16.36% ROE24.50% 52W Range340.09 - 543.55 Perf YTD3.73%
Dividend- P/FCF51.18 EPS past 5Y38.80% ROI18.20% 52W High-29.67% Beta1.52
Dividend %- Quick Ratio3.30 Sales past 5Y61.30% Gross Margin93.40% 52W Low12.41% ATR11.50
Employees5400 Current Ratio3.60 Sales Q/Q23.00% Oper. Margin34.20% RSI (14)44.82 Volatility2.89% 2.85%
OptionableYes Debt/Eq0.12 EPS Q/Q45.90% Profit Margin23.20% Rel Volume0.91 Prev Close380.78
ShortableYes LT Debt/Eq0.12 EarningsNov 08 BMO Payout0.00% Avg Volume903.08K Price382.29
Recom2.30 SMA200.44% SMA50-7.18% SMA200-12.35% Volume99,521 Change0.40%
Dec-01-17Downgrade Citigroup Buy → Neutral $480 → $380
Nov-09-17Reiterated RBC Capital Mkts Sector Perform $473 → $425
Oct-24-17Resumed Guggenheim Buy $540
Oct-20-17Downgrade Barclays Equal Weight → Underweight $450 → $395
Sep-29-17Resumed Piper Jaffray Overweight $540
Sep-15-17Initiated RBC Capital Mkts Sector Perform $475
Sep-06-17Resumed Raymond James Outperform $566
Aug-17-17Initiated Evercore ISI Outperform $605
Aug-04-17Reiterated UBS Buy $489 → $535
Aug-01-17Downgrade Robert W. Baird Neutral → Underperform $408
Jun-30-17Reiterated BTIG Research Buy $480 → $540
Jun-26-17Downgrade Bernstein Outperform → Mkt Perform
Jun-20-17Reiterated Piper Jaffray Overweight $446 → $557
May-05-17Upgrade Canaccord Genuity Hold → Buy $375 → $484
Mar-29-17Reiterated UBS Buy $435 → $446
Mar-17-17Initiated Oppenheimer Perform
Mar-09-17Initiated UBS Buy $435
Feb-16-17Downgrade Goldman Buy → Neutral
Jan-06-17Reiterated RBC Capital Mkts Outperform $626 → $598
Jan-06-17Reiterated Chardan Capital Markets Neutral $350 → $345
Dec-11-17 07:54AM  Biopharma Schizophrenia: High Demand For Innovation Vs. Pleas For 'Me-Too' Drugs Forbes
07:00AM  Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA® (aflibercept) Injection for Patients with Wet AMD PR Newswire
03:22AM  Regeneron (REGN) Down 8.3% Since Earnings Report: Can It Rebound? Zacks
Dec-08-17 09:36AM  The Zacks Analyst Blog Highlights: Netflix, Stamps.com, Constellation Brands and Regeneron Pharmaceuticals Zacks
Dec-06-17 01:18PM  This Double Whammy Caused Regeneron Pharmaceuticals Inc. to Fall 10% in November Motley Fool
Dec-04-17 04:18PM  Amgen, Regeneron Prep For Battle In 2018 Over Cholesterol Drugs Investor's Business Daily
01:45PM  Analysts Recommendations for Regeneron Market Realist
12:15PM  How Regenerons Eylea and Praluent Performed in 3Q17 Market Realist
10:45AM  How Regeneron Pharmaceuticals Performed in 3Q17 Market Realist
Dec-01-17 09:57AM  Citi Downgrades Regeneron, Citing 'Underappreciated' Risk Benzinga
08:07AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
Nov-30-17 06:28PM  Patent Move Was Nuts, Regeneron CEO Tells Allergan Chief Bloomberg
02:44PM  Regeneron CEO: Our genetics research is in the 'precompet... CNBC Videos
11:30AM  Here"s What"s Unusual About Regeneron Pharmaceuticals" Latest Deal GuruFocus.com
08:07AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
07:30AM  Tesla Is the Exception That Proves the Rule on Board Pay Bloomberg
Nov-29-17 08:08AM  Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal Zacks
07:00AM  [$$] Decibel Therapeutics, Regeneron Strike Deal for Hearing Treatments The Wall Street Journal
07:00AM  Regeneron and Decibel Therapeutics Announce Strategic Collaboration to Discover and Develop Therapeutics for Hearing Loss and Tinnitus PR Newswire
Nov-28-17 01:30PM  What's Next For Regeneron After A Therapy Trial Failure? Benzinga
12:27PM  US and European Stocks in Green Tuesday GuruFocus.com
09:48AM  Regeneron Pharmaceuticals: Look but Don't Touch This Bruised Stock Just Yet TheStreet.com
09:42AM  Regeneron's Stock Falls as Mid-Stage Eye Disease Studies Fail Zacks
08:24AM  Regeneron Pharmaceuticals: Look but Don't Touch Just Yet TheStreet.com
Nov-27-17 04:24PM  Regeneron Dips To 7-Month Low After Drug Combo With Bayer Fails Investor's Business Daily
10:45AM  Regeneron's Eylea Protection Is Weakening Bloomberg
08:46AM  Regeneron stock declines 2% on abandoned eye disease therapy MarketWatch
08:07AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
07:20AM  Regeneron drops eye-drug combination as Novartis chases Eylea Reuters
02:00AM  Regeneron Provides Update on EYLEA® (aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program PR Newswire
Nov-24-17 08:07AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
Nov-20-17 08:08AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
Nov-17-17 07:11PM  Cramers Exec Cut: The consumer trends business leaders h... CNBC Videos
Nov-15-17 09:30AM  Regeneron Announces Upcoming Investor Conference Presentation PR Newswire
08:07AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
07:32AM  Inside Novartiss Ophthalmology Drugs Now Market Realist
06:37AM  Regeneron Pharmaceuticals: Cramer's Top Takeaways TheStreet.com
Nov-14-17 07:10PM  Regeneron CEO: Competitor Novartis is 'long on enthusiasm... CNBC Videos
07:10PM  Cramer Remix: My leftover question for GE is 'Did you mis... CNBC Videos
08:07AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
Nov-13-17 12:23PM  Poor earnings updates keep European shares at seven-week low Reuters
Nov-10-17 06:40PM  Edited Transcript of REGN earnings conference call or presentation 8-Nov-17 1:30pm GMT Thomson Reuters StreetEvents
05:42PM  Novartis posts eye drug data amid play for Eylea's turf Reuters
Nov-09-17 10:53AM  When Will Biotech Bounce Back? Barrons.com
08:28AM  Biotech Stock Roundup: Regeneron Delivers Strong Q3 Results, Cellectis Clinical Hold Lifted Zacks
Nov-08-17 06:10PM  Regeneron President on Future of Health Care Bloomberg Video
04:43PM  Regeneron Jumps After Issuing Street-Topping Revenue, Earnings Investor's Business Daily
03:15PM  Regeneron sales jump 23 percent driven by Eylea and new eczema drug American City Business Journals
01:19PM  Did Regeneron Pharmaceuticals Inc (REGN) Create Value For Shareholders? Simply Wall St.
12:16PM  Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up Zacks
11:57AM  A Bright Spot in Blemished Biotech Barrons.com
11:39AM  US STOCKS-Wall Street loses steam as banks, energy stocks weigh Reuters
11:21AM  Regeneron's Long-Term Issues Linger Bloomberg
10:05AM  US STOCKS-Wall Street edges lower as bank stocks weigh Reuters
08:43AM  US STOCKS-Wall St set to open flat with tax bill debate in focus Reuters
08:09AM  Regeneron (REGN) Q3 Earnings Beat Estimates Zacks
07:50AM  Regeneron's stock rallies after profit and sales rise above expectations MarketWatch
07:22AM  Regeneron beats Street 3Q forecasts Associated Press
06:56AM  Regeneron's quarterly profit tops estimates on Eylea sales Reuters
06:38AM  Drugmaker Regeneron's quarterly profit surges 47 pct Reuters
06:30AM  Regeneron Reports Third Quarter 2017 Financial and Operating Results PR Newswire
06:20AM  REGENERON PHARMACEUTICALS INC to Host Earnings Call ACCESSWIRE
Nov-07-17 10:01AM  Here's Why Regeneron Pharmaceuticals Inc. Slipped 10% in October Motley Fool
08:20AM  Consolidated Research: 2018 Summary Expectations for Take-Two, CME Group, Intuit, Henry Schein, VeriSign, and Regeneron Fundamental Analysis, Key Performance Indications GlobeNewswire
08:00AM  Regeneron and Sanofi to Present New Analyses from the Praluent® (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017 PR Newswire
Nov-03-17 06:24PM  What's in the Cards for Adverum (ADVM) This Earnings Season? Zacks
01:52PM  Regeneron Pharmaceuticals Gains A Bull Ahead Of Earnings Benzinga
12:30PM  Chart School: Using Regeneron's Five-Year Rally to Study Support Investor's Business Daily
11:06AM  Regeneron Gets Another Shot Barrons.com
10:21AM  Will Regeneron Pharma (REGN) Disappoint in Q3 Earnings? Zacks
Nov-01-17 09:18AM  Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regenerons PD-1 Inhibitor GlobeNewswire
09:00AM  Regeneron to Share Clinical Progress of REGN1979 and Cemiplimab (REGN2810) in B-Cell Lymphomas at the 2017 ASH Annual Meeting PR Newswire
Oct-31-17 07:00AM  Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in Phase 3 Study of People with Severe Steroid-Dependent Asthma PR Newswire
Oct-30-17 07:01PM  Cramer's lightning round: Not a great run for Southwest A... CNBC Videos
Oct-27-17 05:50PM  Analyst Recommendations for Vertex Pharmaceuticals in October Market Realist
07:00AM  Regeneron's First Global Day of Service Supports Over 100 Non-Profit and Community Organizations PR Newswire
Oct-24-17 08:17AM  Is Regeneron Pharmaceuticals, Inc. Stock a Buy? Motley Fool
Oct-20-17 03:57PM  Another Regeneron Bear Is Born Barrons.com
08:47AM  Pharma Stock Roundup: Beat & Raise Quarter from J&J, Allergan Hit by Restasis Ruling Zacks
Oct-19-17 02:30PM  Science Magazine Ranks Regeneron #1 Biopharma Employer for Fifth Time PR Newswire
08:06AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
Oct-18-17 07:32AM  Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug Zacks
Oct-17-17 12:58PM  Regeneron-Sanofi drug succeeds mid-stage study Reuters
10:48AM  Sanofi/Regeneron's Dupixent Succeeds in Phase II Study Zacks
08:39AM  Gilead Sciences on the Street: Analyst Recommendations in October Market Realist
Oct-16-17 06:16PM  UPDATE 1-Regeneron-Sanofi drug succeeds mid-stage study Reuters
09:19AM  Aimmune teams with Regeneron, Sanofi on peanut allergy drug Reuters
08:17AM  Regeneron-Sanofi throat infection drug succeeds key study Reuters
08:01AM  6 Top Biotech Companies In Innovation Earn Recognition In New Awards Investor's Business Daily
08:00AM  Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis PR Newswire
07:49AM  Regeneron Advances Science To Attack Arthritis, Eye Disease, More Investor's Business Daily
07:42AM  Dupixent May Be Strong Growth Driver for Sanofi in the Future Market Realist
07:20AM  Drugmakers Are Planning to Start a Phase 2 Trial to Cure Peanut Allergy Bloomberg
Oct-12-17 10:31AM  Pres Trump believes he has the cure for Obamacare Yahoo Finance Video
Oct-11-17 05:58PM  Dow's Merck Bails On Cholesterol Drug, Prodding Shares Down Investor's Business Daily
09:30AM  Regeneron to Report Third Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on November 8, 2017 PR Newswire
08:07AM  Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit Zacks
08:00AM  Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis PR Newswire
Oct-10-17 04:57PM  This Biotech Hit Record High; Could Undercut Regeneron In Eczema Investor's Business Daily
Oct-09-17 02:28PM  [$$] Ruling Goes Regeneron's Way Barrons.com
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children's. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor. It also has collaboration agreements with Intellia Therapeutics, Inc. to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development; and the U.S. Department of Health and Human Services to develop treatments combating infectious diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BROWN MICHAEL SDirectorOct 05Option Exercise177.821,500266,7301,500Oct 05 04:18 PM
BROWN MICHAEL SDirectorOct 05Sale475.001,500712,5000Oct 05 04:18 PM
BAKER CHARLES ADirectorSep 29Option Exercise18.612,00037,22011,000Oct 03 04:00 PM
BAKER CHARLES ADirectorSep 29Sale450.002,000900,0009,000Oct 03 04:00 PM
Landry Robert ESVP Finance & CFOSep 06Sale497.62474235,8737,099Sep 06 05:06 PM
Landry Robert ESVP Finance & CFOSep 05Sale501.0618994,7007,573Sep 06 05:06 PM
Landry Robert ESVP Finance & CFOSep 01Option Exercise272.703,000818,10010,099Sep 06 05:06 PM
Landry Robert ESVP Finance & CFOAug 31Sale493.43427210,6937,099Sep 01 04:04 PM
Landry Robert ESVP Finance & CFOAug 30Option Exercise272.702,000545,4009,099Sep 01 04:04 PM
Landry Robert ESVP Finance & CFOAug 23Sale476.45468222,9817,099Aug 24 04:47 PM
Landry Robert ESVP Finance & CFOAug 22Option Exercise272.702,000545,4009,099Aug 24 04:47 PM
VAGELOS P ROYChairman of the BoardAug 22Sale477.6431,94415,257,816329,543Aug 23 04:21 PM
VAGELOS P ROYChairman of the BoardAug 21Sale470.3224,26911,414,076361,487Aug 23 04:21 PM
VAGELOS P ROYChairman of the BoardAug 18Sale470.152,9001,363,435385,756Aug 18 05:00 PM
VAGELOS P ROYChairman of the BoardAug 17Sale470.001,305613,350388,656Aug 18 05:00 PM
VAGELOS P ROYChairman of the BoardAug 16Option Exercise21.92153,9693,375,000483,512Aug 18 05:00 PM
VAGELOS P ROYChairman of the BoardAug 16Sale470.1710,9865,165,288389,961Aug 18 05:00 PM
Terifay Robert JEVP CommercialAug 10Option Exercise52.031,92199,95025,214Aug 11 04:02 PM
Landry Robert ESVP Finance & CFOAug 08Sale472.19526248,3727,099Aug 09 04:03 PM
Landry Robert ESVP Finance & CFOAug 07Option Exercise272.702,000545,4009,099Aug 09 04:03 PM
STAHL NEILEVP Research and DevelopmentJun 22Sale532.558,3064,423,33223,950Jun 23 04:09 PM
Aberman Michael SSVP Strategy Investor RelationJun 22Sale532.422,2691,208,0614,693Jun 23 04:10 PM
Aberman Michael SSVP Strategy Investor RelationJun 21Option Exercise30.634,500137,8359,193Jun 23 04:10 PM
STAHL NEILEVP Research and DevelopmentJun 21Option Exercise30.6320,000612,60043,950Jun 23 04:09 PM
BROWN MICHAEL SDirectorJun 20Option Exercise177.823,000533,4603,000Jun 21 04:11 PM
GOLDSTEIN JOSEPH LDirectorJun 20Option Exercise273.671,000273,67014,000Jun 21 04:12 PM
BROWN MICHAEL SDirectorJun 20Sale500.003,0001,500,0000Jun 21 04:11 PM
GOLDSTEIN JOSEPH LDirectorJun 20Sale500.011,000500,01013,000Jun 21 04:12 PM
Terifay Robert JEVP CommercialJun 16Sale468.1921,1479,900,81423,293Jun 19 04:44 PM
Terifay Robert JEVP CommercialJun 15Option Exercise52.0348,7502,536,46372,043Jun 19 04:44 PM
STAHL NEILEVP Research and DevelopmentJun 15Sale468.458,5674,013,17723,950Jun 16 04:36 PM
STAHL NEILEVP Research and DevelopmentJun 14Option Exercise21.2520,295431,26944,245Jun 16 04:36 PM
BROWN MICHAEL SDirectorJun 12Option Exercise177.822,000355,6402,000Jun 14 04:36 PM
BROWN MICHAEL SDirectorJun 12Sale474.452,000948,8900Jun 14 04:36 PM
GOLDSTEIN JOSEPH LDirectorJun 09Option Exercise273.671,000273,67014,000Jun 13 05:06 PM
GOLDSTEIN JOSEPH LDirectorJun 09Sale482.551,000482,55013,000Jun 13 05:06 PM
STAHL NEILEVP Research and DevelopmentJun 02Sale479.492,8121,348,31423,950Jun 05 04:52 PM
STAHL NEILEVP Research and DevelopmentJun 01Option Exercise198.3810,5442,091,72430,814Jun 05 04:52 PM
VAGELOS P ROYChairman of the BoardMay 25Sale458.149,2954,258,37383,652May 26 04:04 PM
BROWN MICHAEL SDirectorMay 12Option Exercise177.823,000533,4603,000May 15 04:07 PM
BROWN MICHAEL SDirectorMay 12Sale450.003,0001,350,0000May 15 04:07 PM
BROWN MICHAEL SDirectorMar 29Option Exercise177.821,000177,8201,000Mar 30 04:42 PM
BROWN MICHAEL SDirectorMar 29Sale400.001,000400,0000Mar 30 04:42 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 15Option Exercise20.32195,0793,964,005697,000Dec 19 04:09 PM
SCHLEIFER LEONARD SPresident & CEODec 15Option Exercise20.32250,0005,080,000292,806Dec 19 04:07 PM
BAKER CHARLES ADirectorDec 12Option Exercise18.613,00055,83012,000Dec 14 05:41 PM
BAKER CHARLES ADirectorDec 12Sale392.023,0001,176,0489,000Dec 14 05:41 PM